全文获取类型
收费全文 | 594篇 |
免费 | 56篇 |
出版年
2022年 | 8篇 |
2021年 | 15篇 |
2020年 | 13篇 |
2019年 | 13篇 |
2018年 | 10篇 |
2017年 | 5篇 |
2016年 | 13篇 |
2015年 | 21篇 |
2014年 | 28篇 |
2013年 | 29篇 |
2012年 | 60篇 |
2011年 | 46篇 |
2010年 | 30篇 |
2009年 | 16篇 |
2008年 | 37篇 |
2007年 | 44篇 |
2006年 | 41篇 |
2005年 | 32篇 |
2004年 | 36篇 |
2003年 | 18篇 |
2002年 | 23篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1995年 | 5篇 |
1994年 | 2篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 8篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 5篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1974年 | 4篇 |
1973年 | 7篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1964年 | 2篇 |
排序方式: 共有650条查询结果,搜索用时 78 毫秒
141.
To date, data are not available concerning the effectiveness of chemotherapy in the treatment of Spirocerca lupi-associated esophageal sarcomas. In the present study, we compared the effectiveness of 4 chemotherapeutic agents against S. lupi-associated osteosarcoma, using a xenograft murine model created in our lab. Samples of xenografted osteosarcoma were inoculated subcutaneously into 5 groups (n = 10 each) of 6-wk-old male and female NOD/SCID mice. Tumor-bearing mice were divided into treatment and control groups. The treatment groups were injected with either pegylated liposomal doxorubicin (6 mg/kg, intravenously, n = 9), doxorubicin (6 mg/kg, intravenously, n = 8), carboplatin (60 mg/kg, intraperitoneally, repeated twice at 1-wk intervals for a total of 2 doses, n = 9), or cisplatin (6 mg/kg, intraperitoneally, n = 8). The control group was injected with buffered saline (n = 9). Tumor size was determined by caliper measurements. Compared with the control group, the pegylated liposomal doxorubicin- and doxorubicin-treated groups, but not the carboplatin or cisplatin groups, showed significant inhibition of tumor growth. Our results indicate that doxorubicin-based drugs are effective against S. lupi-associated sarcomas in a mouse xenograft model. Because it is less toxic than doxorubicin, pegylated liposomal doxorubicin is likely the drug of choice for treatment of S. lupi-associated sarcomas. We suggest that combination of doxorubicin or its pegylated form with surgical excision will improve the prognosis of dogs with this disease. 相似文献
142.
Francesca Patella Zachary T. Schug Erez Persi Lisa J. Neilson Zahra Erami Daniele Avanzato Federica Maione Juan R. Hernandez-Fernaud Gillian Mackay Liang Zheng Steven Reid Christian Frezza Enrico Giraudo Alessandra Fiorio Pla Kurt Anderson Eytan Ruppin Eyal Gottlieb Sara Zanivan 《Molecular & cellular proteomics : MCP》2015,14(3):621-634
Endothelial cells (ECs) play a key role to maintain the functionality of blood vessels. Altered EC permeability causes severe impairment in vessel stability and is a hallmark of pathologies such as cancer and thrombosis. Integrating label-free quantitative proteomics data into genome-wide metabolic modeling, we built up a model that predicts the metabolic fluxes in ECs when cultured on a tridimensional matrix and organize into a vascular-like network. We discovered how fatty acid oxidation increases when ECs are assembled into a fully formed network that can be disrupted by inhibiting CPT1A, the fatty acid oxidation rate-limiting enzyme. Acute CPT1A inhibition reduces cellular ATP levels and oxygen consumption, which are restored by replenishing the tricarboxylic acid cycle. Remarkably, global phosphoproteomic changes measured upon acute CPT1A inhibition pinpointed altered calcium signaling. Indeed, CPT1A inhibition increases intracellular calcium oscillations. Finally, inhibiting CPT1A induces hyperpermeability in vitro and leakage of blood vessel in vivo, which were restored blocking calcium influx or replenishing the tricarboxylic acid cycle. Fatty acid oxidation emerges as central regulator of endothelial functions and blood vessel stability and druggable pathway to control pathological vascular permeability.Endothelial cells (ECs)1 line the inner layer of the blood vessel wall and constitute a barrier between blood and surrounding tissue. As such, a tight regulation of EC permeability is crucial to maintain vessel functionality and avoid excessive extravasation of fluid and plasma proteins (1). Increased endothelial permeability is typical in inflammatory states and a hallmark of diseases such thrombosis, atherosclerosis, and cancer (2, 3). Because of their unique localization, ECs are constantly exposed to oxygen and nutrients that fuel cell metabolism and whose levels vary in physiological and pathological conditions. Yet, how cell metabolism regulates endothelial permeability remains incompletely understood.Previous studies have reported that EC cultures use glucose as predominant source of energy by producing lactate through glycolysis. However, also fatty acids and glutamine contribute to ATP and metabolic intermediate production (4–7). Recent in vivo studies have shown that glycolysis is necessary for EC proliferation and motility in physiological and pathological angiogenesis (4, 8). Moreover, the peroxisome proliferator-activated receptor gamma coactivator 1-α, which can activate oxidative phosphorylation, blocks EC sprouting in diabetes (9). The intriguing information emerging from these studies is that key metabolic pathways, such as glycolysis and oxidative phosphorylation in the mitochondria, play an important role in ECs and that they are actively involved in the regulation of key cell functions.Mitochondrial fatty acid oxidation (FAO) is the process that converts fatty acids (FAs) into acetyl-CoA, which fuels the tricarboxylic acid cycle (TCAc) and generates reducing factors for producing ATP via oxidative phosphorylation. Cells can incorporate FAs from the culture media or can generate FAs from the hydrolysis of triglycerides or through de novo synthesis. FAs, then, can access the mitochondria according to their length; whereas short and medium-chain FAs (up to 12 carbon atoms) diffuse through the mitochondrial membrane, long-chain FAs (with 13–21 carbon atoms) are actively transported by the carnitine O-palmitoyl transferase (CPT) proteins, which are rate-limiting enzymes for this pathway (10). Previous work suggested that FAO is poorly utilized by EC cultures (4), however, under certain stress conditions such as glucose deprivation, FAO becomes a major source of energy (7). Although it is striking to note how cells can adapt and remodel their metabolism, the role of key FAO enzymes in the control of EC functions is still largely unclear.Because of the complexity of the cell metabolome, global-scale metabolomic studies for in depth and quantitative analysis of metabolic fluxes are still challenging and computational models have provided invaluable help to better understand cell metabolism. Among them, the integrative metabolic analysis tool (iMAT), which integrates gene expression data with genome-scale metabolic network model (GSMM), has been successfully used to predict enzyme metabolic flux in several model systems and diseases (11, 12). Because gene expression and protein levels do not always correlate, and because enzymes levels do not necessarily reflect their enzymatic activity or the flux of the reaction that they are involved in, iMAT uses expression data as cue for the likelihood, but not final determinant, of enzyme activity. Modern MS technology and robust approaches for protein quantification, such as stable-isotope labeling with amino acids in cell culture (SILAC) (13) and advanced label-free algorithms (14), allow global comparative proteomic analysis and accurate measurements of protein and post-translational modification levels (15). We reasoned that the integration of quantitative MS-proteomic data into GSMM could contribute to the study of cell metabolism. Moreover, metabolic changes trigger activation of protein kinases (16, 17) to rapidly remodel the intracellular signaling and enable cells to adapt to these sudden alterations. Protein phosphorylation therefore plays an important role in regulating cell response to metabolic alteration and may hide information on cellular pathways and functions controlled by specific metabolic activities. MS-based proteomic approaches therefore offer an additional opportunity to investigate in an unbiased manner the interplay between cell metabolism and cell function (18).We have previously shown (19) that when human primary ECs are cultured for 1 day on the three-dimensional matrix matrigel and assemble into a complex network, a simplified model that recapitulates some aspects of vascular network assembly in vivo (20), the levels of metabolic enzymes are profoundly regulated. This result suggested an interplay between cell metabolism and EC behavior. Here we investigate further this aspect. Integrating label-free quantitative MS-proteomics, predictive metabolic modeling and metabolomics we discovered increased FAO when ECs are assembled into a fully formed network. Moreover, by inhibiting CPT1 pharmacologically, we elucidated that FAO is a central regulator of EC permeability in vitro and blood vessel stability in vivo. Thus, proteomics significantly contributes to the study of cell metabolism and here we identified FAO as a promising target for therapeutic intervention for the control of pathological vascular permeability. 相似文献
143.
Cancer cells have fundamentally altered cellular metabolism that is associated with their tumorigenicity and malignancy. In addition to the widely studied Warburg effect, several new key metabolic alterations in cancer have been established over the last decade, leading to the recognition that altered tumor metabolism is one of the hallmarks of cancer. Deciphering the full scope and functional implications of the dysregulated metabolism in cancer requires both the advancement of a variety of omics measurements and the advancement of computational approaches for the analysis and contextualization of the accumulated data. Encouragingly, while the metabolic network is highly interconnected and complex, it is at the same time probably the best characterized cellular network. Following, this review discusses the challenges that genome‐scale modeling of cancer metabolism has been facing. We survey several recent studies demonstrating the first strides that have been done, testifying to the value of this approach in portraying a network‐level view of the cancer metabolism and in identifying novel drug targets and biomarkers. Finally, we outline a few new steps that may further advance this field. 相似文献
144.
Chloroplasts of higher plants develop from proplastids, which are undifferentiated plastids that lack photosynthetic (thylakoid) membranes. In flowering plants, the proplastid-chloroplast transition takes place at the shoot apex, which consists of the shoot apical meristem (SAM) and the flanking leaf primordia. It has been believed that the SAM contains only proplastids and that these become chloroplasts only in the primordial leaves. Here, we show that plastids of the SAM are neither homogeneous nor necessarily null. Rather, their developmental state varies with the specific region and/or layer of the SAM in which they are found. Plastids throughout the L1 and L3 layers of the SAM possess fairly developed thylakoid networks. However, many of these plastids eventually lose their thylakoids during leaf maturation. By contrast, plastids at the central, stem cell-harboring region of the L2 layer of the SAM lack thylakoid membranes; these appear only at the periphery, near the leaf primordia. Thus, plastids in the SAM undergo distinct differentiation processes that, depending on their lineage and position, lead to either development or loss of thylakoid membranes. These processes continue along the course of leaf maturation. 相似文献
145.
Purine nucleoside phosphorylase (PNP) is an intracellular enzyme crucial for purine degradation. PNP defects result in metabolic abnormalities and fatal T cell immunodeficiency. Protein transduction domains (PTD) transfer molecules across biological membranes. We hypothesized that fusion of PTD to PNP (PTD-PNP) would be an effective method for treating PNP deficiency. We find that PTD-PNP rapidly enters PNP-deficient lymphocytes and increases intracellular enzyme activity for 96 h. Similar to endogenous PNP, PTD-PNP is predominantly distributed in the cytoplasm. PTD-PNP improve viability and correct abnormal functions of PNP-deficient T lymphocytes including their response to stimulation and IL-2 secretion. Intracellular transduction protects PTD-PNP from antibody neutralization and from elimination, which may also provide significant in vivo therapeutic advantages to PNP. In conclusion, PTD fusion is an attractive method for extended PNP intracellular enzyme replacement therapy for PNP-deficient patients as well as for the intracellular delivery of other proteins. 相似文献
146.
Shafat I Zcharia E Nisman B Nadir Y Nakhoul F Vlodavsky I Ilan N 《Biochemical and biophysical research communications》2006,341(4):958-963
Heparanase is a mammalian endo-beta-D-glucuronidase that cleaves heparan sulfate side chains at a limited number of sites. Heparanase enzymatic activity is thought to participate in degradation and remodeling of the extracellular matrix and to facilitate cell invasion associated with tumor metastasis, angiogenesis, and inflammation. Traditionally, heparanase activity was well correlated with the metastatic potential of a large number of tumor-derived cell types. More recently, heparanase upregulation was detected in an increasing number of primary human tumors, correlating, in some cases, with poor postoperative survival and increased tumor vascularity. The present study was undertaken to develop a highly sensitive ELISA suitable for the determination and quantification of human heparanase in tissue extracts and body fluids. The assay preferentially detects the 8+50 kDa active heparanase heterodimer vs. the latent 65 kDa proenzyme and correlates with immunoblot analysis of heparanase containing samples. It detects heparanase at concentrations as low as 200 pg/ml and is suitable for quantification of heparanase in tissue extracts and urine. 相似文献
147.
148.
149.
Background
Regulatory T cells (Tregs) were shown to be central in maintaining immunological homeostasis and preventing the development of autoimmune diseases. Several subsets of Tregs have been identified to date; however, the dynamics of the interactions between these subsets, and their implications on their regulatory functions are yet to be elucidated.Methodology/Principal Findings
We employed a combination of mathematical modeling and frequent in vivo measurements of several T cell subsets. Healthy BALB/c mice received a single injection of either hCDR1 - a tolerogenic peptide previously shown to induce Tregs, a control peptide or vehicle alone, and were monitored for 16 days. During this period, splenocytes from the treated mice were analyzed for the levels of CD4, CD25, CD8, CD28 and Foxp3. The collected data were then fitted to mathematical models, in order to test competing hypotheses regarding the interactions between the followed T cell subsets. In all 3 treatment groups, a significant, lasting, non-random perturbation of the immune system could be observed. Our analysis predicted the emergence of functional CD4 Tregs based on inverse oscillations of the latter and CD4+CD25− cells. Furthermore, CD4 Tregs seemed to require a sufficiently high level of CD8 Tregs in order to become functional, while conversion was unlikely to be their major source. Our results indicated in addition that Foxp3 is not a sufficient marker for regulatory activity.Conclusions/Significance
In this work, we unraveled the dynamics of the interplay between CD4, CD8 Tregs and effector T cells, using, for the first time, a mathematical-mechanistic perspective in the analysis of Treg kinetics. Furthermore, the results obtained from this interdisciplinary approach supported the notion that CD4 Tregs need to interact with CD8 Tregs in order to become functional. Finally, we generated predictions regarding the time-dependent function of Tregs, which can be further tested empirically in future work. 相似文献150.
Naresh M. Punjabi Brian S. Caffo James L. Goodwin Daniel J. Gottlieb Anne B. Newman George T. O'Connor David M. Rapoport Susan Redline Helaine E. Resnick John A. Robbins Eyal Shahar Mark L. Unruh Jonathan M. Samet 《PLoS medicine》2009,6(8)